Journal of Clinical Medicine Submission Guide: MDPI Process (2026)

The Journal of Clinical Medicine is not a stronger version of a subscription clinical journal, and it is not a weaker one. It is a different model. MDPI built it around speed and soundness-based review: the editorial question is whether the work is methodologically sound, ethically clean, and within clinical scope, not whether it ranks among the most practice-changing findings of the year. That model shapes everything about how you should prepare the package.

The contrast with the selective flagships is the cleanest way to understand the fit. The Lancet, JAMA, and NEJM run a novelty-and-impact filter: a professional editor desk-rejects most submissions within days because the result will not change practice broadly enough, regardless of how clean the methods are. The Journal of Clinical Medicine inverts that.

A sound single-center cohort that the Lancet would desk-reject for limited impact can be a fully appropriate, in-scope contribution here, provided it is reported correctly and framed honestly. If your study is rigorous but incremental, this is the right tier; if it would genuinely reset a clinical guideline, the selective flagships are the better target.

Two consequences matter most. First, the journal is section-based and organized by clinical specialty (cardiology, ophthalmology, nephrology, oncology, and many more), so scope fit is assessed against a specific section rather than a vague "is this interesting" bar. Second, the pre-check is fast and partly template-driven, so completeness is rewarded and incompleteness is punished early. A technically sound study with a missing trial registration or an incomplete consent statement can be returned before a reviewer ever sees it, while a competent, complete, in-scope clinical study moves quickly.

The journal also runs a heavy program of guest-edited Special Issues. A large share of content arrives through these calls, and a submission routed to a relevant Special Issue often moves faster because a topic editor is already assigned. That is an opportunity, not a shortcut: Special Issue manuscripts pass the same pre-check and the same single-blind review as regular submissions, so the readiness bar does not change.

The honest tradeoff: what speed costs you

The speed is real, but be honest with yourself about the tradeoff before you submit. A soundness-based model that returns a decision in under three weeks does not carry the brand signal of a selective flagship, and the heavy Special Issue volume means your paper sits in a large, fast-moving corpus rather than a tightly curated table of contents.

For a clinical author whose promotion case rests on journal prestige, that is a genuine cost; for an author who needs a rigorous, open-access, PubMed-indexed home with a quick decision, it is exactly the right trade. Name which one you are before you commit the APC.

The core fit for most submissions is the original research article reporting a clinical study: a single-center cohort, a registry analysis, a diagnostic-accuracy study, or a randomized trial. It works best when the clinical question is central, the methods are reproducible from the text, and the declarations and reporting package are complete on first upload.

Ask these questions before you submit:

• is the clinical question the actual subject of the paper, or is the clinical angle a downstream application of a basic-science finding?
• can a reader reproduce the methods, cohort definition, and statistical analysis from the manuscript and supplementary files alone?
• are the ethics, consent, and registration statements complete and specific, or are they still stub text?
• does the reporting follow the checklist that matches the study design?

If the answers are uncertain, the pre-check problem is usually more important than the science problem.

The pre-check editor is answering a short list of questions fast.

On scope, the editor asks whether the manuscript belongs in a clinical journal and in which specialty section. If the clinical relevance is thin or bolted on (a cell-line experiment with a one-line clinical implication), the paper is redirected or returned. On soundness, the question is whether the design is appropriate, the sample is adequately described, and the statistical analysis matches the stated objectives.

The Journal of Clinical Medicine does not require the finding to be field-defining, but it does require the work to be done correctly and reported in full.

On integrity, the editor checks whether ethics approvals, informed consent, trial or protocol registration, and data availability are all in order. MDPI runs integrity and plagiarism checks at pre-check, and gaps here trigger fast returns. On completeness, the editor looks for the declarations block. A manuscript missing Author Contributions, Funding, or Conflicts of Interest reads as not ready, even when the clinical science is fine.

Here is the part authors underweight: at a soundness-based clinical journal, the editor is not asking whether your single-center study will change practice. They are asking whether you have claimed it will. A clean observational cohort that says "these associations warrant a prospective trial" clears pre-check; the same cohort that says "our findings establish a new standard of care" reads as overreach, and overreach is the fastest route to a reviewer asking for the claims to be walked back.

Manuscript structure: The Journal of Clinical Medicine expects a defined section set: Abstract, Keywords, Introduction, Materials and Methods, Results, Discussion, Conclusions, plus the declarations block. Original research and systematic reviews need a structured abstract of around 200 words under Background/Objectives, Methods, Results, and Conclusions headings. The abstract is the first thing the pre-check editor reads, so the clinical question, the study design, and the main result all need to be visible there.

Reporting and methods readiness: Provide full clinical detail so results can be reproduced, and follow the design-appropriate guideline: CONSORT for randomized trials (with the flow diagram and the completed checklist), STROBE for observational cohort, case-control, and cross-sectional studies, PRISMA for systematic reviews and meta-analyses (with a PROSPERO-registered protocol), CARE for case reports, and STARD for diagnostic-accuracy studies. A clinical paper that does not map cleanly onto its reporting checklist is the most common reviewer-stage friction point.

Declarations and ethics: Draft the Institutional Review Board statement (with the approval number), the Informed Consent statement, the trial or protocol registration identifier, Author Contributions (by initials), Funding, Data Availability, and Conflicts of Interest sections before you upload. These are not post-acceptance paperwork at MDPI; they are pre-check gates.

Figures, supplementary, and clinical-study assets: Clinical manuscripts live or die on their study-flow assets. A randomized trial needs a CONSORT flow diagram showing enrollment, allocation, follow-up, and analysis numbers; an observational study needs a participant-flow figure consistent with STROBE; a systematic review needs a PRISMA flow diagram. Patient-cohort and baseline-characteristics tables should report group sizes, the statistical test used, and exact p-values rather than "NS."

A graphical abstract is optional but commonly used; if supplied, it should be a high-resolution PNG, JPEG, or TIFF. De-identify all patient images, scans, and supplementary case data, and confirm consent-to-publish for any identifiable material. ORCID is expected for the submitting author, and the system will ask for suggested reviewers.

In our pre-submission review work with Journal of Clinical Medicine manuscripts, three failure patterns generate the most consistent pre-check returns and reviewer friction, and they are testable against your own manuscript before you upload.

Across our clinical pre-submission reviews, the pattern that surprises authors most is that the Journal of Clinical Medicine pre-check is not a quality filter in the NEJM sense; it is a completeness-fit-and-honesty filter. The manuscripts that get returned fastest are rarely bad science. They are competent clinical studies whose declarations block, scope framing, claim calibration, or reporting compliance is not ready for a fast, template-driven screen. Manuscripts coming through pre-submission review for the Journal of Clinical Medicine split cleanly along three lines:

The first is overstated single-center findings: a sound retrospective study from one hospital framed as practice-changing or generalizable. The second is selection and registration gaps: small or non-consecutive cohorts presented as representative, or interventional studies with no trial or protocol registration. The third is reporting-guideline drift: methods and figures that do not map onto CONSORT, STROBE, PRISMA, CARE, or STARD, with the flow diagram missing.

The detail on each, with the testable version you can run against your own draft, follows below.

Single-center retrospective studies framed as practice-changing

Pattern 1: claim calibration outruns the design. The single most common pattern we see is a sound single-center retrospective study whose abstract and conclusions claim generalizable, practice-changing impact. A 140-patient chart review from one hospital is a legitimate contribution at a soundness-based clinical journal, but only if it is framed as one.

When the Discussion says the findings "should change clinical guidelines" or the conclusion calls a small, unadjusted association "definitive," the calibration mismatch is the first thing a reviewer flags, and the editor often returns the paper to soften the claims before review even starts.

The testable version of this failure: read your own conclusion and abstract, and ask whether every claim is supported by the sample size, the design, and the confidence intervals in your results. If a sentence promises more than a single-center retrospective design can deliver, the framing is overreaching, and the fix is to scale the claims to the evidence rather than scaling the language up to impress.

Check whether your Journal of Clinical Medicine claims match your study design →

Small or selected cohorts presented as generalizable, with missing registration

Pattern 2: selection and registration gaps. The second pattern is a small or non-consecutive cohort presented as if it represents the broader patient population, often paired with missing trial or protocol registration. We repeatedly see prospective studies described as randomized with no registration identifier, convenience samples reported without acknowledging selection bias, and underpowered subgroup analyses presented as primary findings.

MDPI treats the ethics statement, the consent statement, and the registration identifier as pre-check gates, so a clinical trial with no ClinicalTrials.gov number or a systematic review with no PROSPERO registration can be returned before review.

The testable version: confirm that your sample size supports the claims you make about generalizability, that selection and inclusion or exclusion criteria are stated explicitly, and that every interventional study or registered review carries its registration number in the Methods and on the title page.

Check whether your Journal of Clinical Medicine cohort and registration are reviewer-ready →

Reporting that does not map onto its clinical guideline checklist

Pattern 3: reporting-guideline drift. The third pattern shows up at the reviewer stage, and it is reporting that does not follow the checklist matching the study design.

A randomized trial with no CONSORT flow diagram, an observational study that ignores STROBE and never reports how confounders were handled, a systematic review with no PRISMA diagram, or a diagnostic study that omits STARD sensitivity and specificity reporting: each one forces reviewers to spend their attention on missing structure rather than on the clinical question.

In clinical medicine, where the credibility of a result hangs on how endpoints, sample sizes, missing data, and statistical analyses are reported, this is the highest-leverage fix before submission. The testable version: identify the guideline that matches your design, walk your manuscript against every checklist item, and supply the completed checklist and the relevant flow diagram in the supplementary files.

If half your checklist items point to "see Methods" without the Methods actually covering them, the reporting is not ready.

Check whether your Journal of Clinical Medicine reporting matches its guideline checklist →

Each of these is something you can check against your own draft before you commit the submission. This guide tells you what Journal of Clinical Medicine editors look for; the review tells you whether YOUR paper passes the pre-check before you upload. We have reviewed 80+ manuscripts targeting open-access clinical journals, including the Journal of Clinical Medicine and its peers.

Paid Manusights reviews include a 60-day money-back guarantee, and we do not train models on submitted manuscripts. Run a Journal of Clinical Medicine submission package check to see whether your scope framing, claim calibration, declarations block, and reporting compliance will clear the MDPI pre-check.

The Journal of Clinical Medicine reports a median first decision near 18.5 days and median acceptance-to-publication near 2.7 days. Treat these as planning ranges, not promises: multicenter clinical trials and large cohort manuscripts often run longer because reviewer search takes time in specialized clinical subfields.

• Day 0: Submission via SuSy. The portal accepts the package and routes it to the section or topic editor for pre-check.

• Days 1 to 3: Editorial pre-check. The editor screens clinical-scope fit, ethics and registration completeness, integrity and plagiarism checks, and basic soundness.

The fastest returns happen here, before any reviewer is invited.

• Days 3 to 7: Reviewer invitation. Manuscripts that pass pre-check enter single-blind reviewer search, typically targeting two or more reviewers in the relevant clinical specialty.

• Days 7 to 18: Peer review and first decision. Reviewer reports return and the editor issues the first decision, with a median near 18.5 days from submission.

Major revision is the most common outcome for papers that clear pre-check.

• Days 19 to 35: Revision and acceptance. Revisions are usually requested on a short clock; resubmission and a second review cycle commonly land acceptance inside a few weeks for in-scope, complete clinical packages.

• Days 35 to 38: Production and publication. Acceptance to publication runs near 2.7 days at median, so the slow part of the calendar is reviewer search and revision, not production.

This is the question clinical authors ask most, because a tenure or grant requirement often hinges on it. The Journal of Clinical Medicine (ISSN 2077-0383) is indexed in PubMed and PubMed Central, the Science Citation Index Expanded in Web of Science, Scopus, and Embase, and it carries a 2024 Clarivate JCR metric of 2.9 (5-year 3.3, CiteScore 5.2) in the Q1 Medicine, General and Internal category.

Worth stating honestly: MDPI has had titles removed from Web of Science before. In March 2023 Clarivate discontinued coverage of two MDPI journals, the International Journal of Environmental Research and Public Health and the Journal of Risk and Financial Management, on content-relevance grounds, and the publisher's mega-journal model has drawn ongoing scrutiny over Special Issue volume.

The Journal of Clinical Medicine was not among the discontinued titles; it retained Web of Science coverage and received an updated JCR citation metric in the June 2024 release. Indexing decisions can change at any review cycle, so confirm the current badges on the journal's own indexing page before you rely on a single database for a hard requirement.

This guide was researched and built from primary sources: the sources we checked include the Journal of Clinical Medicine Instructions for Authors, the journal's aims-and-scope, indexing, and editorial-process pages, MDPI's research and publication ethics policy, the Clarivate Web of Science Master Journal List, and Manusights pre-submission review patterns from clinical manuscripts deciding between the Journal of Clinical Medicine and peer open-access clinical journals. We reviewed and compared current MDPI author guidance with recent Manusights work reviews from authors weighing the Journal of Clinical Medicine, BMJ Open, PLOS ONE, Frontiers in Medicine, and Diagnostics.

Last reviewed by the Manusights clinical editorial team on 2026-06-07.

Source limitations: MDPI can update the APC, article-format details, abstract caps, and editorial-process numbers after this review date, and indexing or impact-factor status is set by Clarivate and Scopus on their own review cycles, so verify final administrative and indexing details against the official Journal of Clinical Medicine author and indexing pages before upload. Median timelines are reported by the journal and vary by specialty.

Use this guide for the decision the official instructions cannot answer: whether your scope framing, claim calibration, declarations block, and reporting compliance are ready for the MDPI pre-check.

• Journal of Clinical Medicine journal profile
• Is BMC Medicine a good journal?
• Is BMJ Open a good journal?
• PLOS ONE vs BMC Medicine: how to choose
• Diagnostics submission guide

Before you upload, run your manuscript through a Journal of Clinical Medicine submission readiness check to catch the scope, claim-calibration, ethics, and reporting gaps the MDPI pre-check filters for. The check is free to run (/ai-review) and takes a single upload.